CN113474374A - 抗FXI/FXIa抗体及其用途 - Google Patents

抗FXI/FXIa抗体及其用途 Download PDF

Info

Publication number
CN113474374A
CN113474374A CN202080014807.4A CN202080014807A CN113474374A CN 113474374 A CN113474374 A CN 113474374A CN 202080014807 A CN202080014807 A CN 202080014807A CN 113474374 A CN113474374 A CN 113474374A
Authority
CN
China
Prior art keywords
antibody
seq
sequence
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080014807.4A
Other languages
English (en)
Inventor
田海军
刘登念
邓俗俊
马克·P·崔西
王成
郑勇
肖亮
薛彤彤
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Konasi Pharmaceutical Co ltd
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Konasi Pharmaceutical Co ltd
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Konasi Pharmaceutical Co ltd, Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Konasi Pharmaceutical Co ltd
Priority to CN202311157496.9A priority Critical patent/CN117186232A/zh
Publication of CN113474374A publication Critical patent/CN113474374A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96452—Factor XI (3.4.21.27)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明属于治疗性单克隆抗体领域，具体而言提供了抗FXI/FXIa的抗体或其抗原结合片段，编码它们的核酸分子，制备它们的方法。本发明的抗FXI/FXIa抗体或其抗原结合片段对FXI/FXIa具有特异性和高亲和力，能够有效抑制FXI/FXIa的活性。因此，本发明进一步提供了包含所述抗体或其抗原结合片段的药物组合物，以及其在制备药物中的用途，所述药物用于预防和/或治疗与凝血或血栓栓塞相关的疾病或病症。

Description

PCT国内申请，说明书已公开。

Claims (30)

  1. PCT国内申请，权利要求书已公开。
CN202080014807.4A 2019-04-16 2020-04-06 抗FXI/FXIa抗体及其用途 Pending CN113474374A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311157496.9A CN117186232A (zh) 2019-04-16 2020-04-06 抗FXI/FXIa抗体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910303627 2019-04-16
CN2019103036277 2019-04-16
PCT/CN2020/083413 WO2020211674A1 (zh) 2019-04-16 2020-04-06 抗FXI/FXIa抗体及其用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311157496.9A Division CN117186232A (zh) 2019-04-16 2020-04-06 抗FXI/FXIa抗体及其用途

Publications (1)

Publication Number Publication Date
CN113474374A true CN113474374A (zh) 2021-10-01

Family

ID=72838014

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080014807.4A Pending CN113474374A (zh) 2019-04-16 2020-04-06 抗FXI/FXIa抗体及其用途
CN202311157496.9A Pending CN117186232A (zh) 2019-04-16 2020-04-06 抗FXI/FXIa抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311157496.9A Pending CN117186232A (zh) 2019-04-16 2020-04-06 抗FXI/FXIa抗体及其用途

Country Status (6)

Country Link
US (1) US20220162338A1 (zh)
EP (1) EP3957652A4 (zh)
JP (1) JP2022528595A (zh)
KR (1) KR20210151774A (zh)
CN (2) CN113474374A (zh)
WO (1) WO2020211674A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023131213A1 (zh) * 2022-01-05 2023-07-13 上海迈晋生物医药科技有限公司 一种包含抗FXI/FXIa抗体的药物组合物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016207858A1 (en) * 2015-06-26 2016-12-29 Novartis Ag Factor xi antibodies and methods of use
WO2017162791A1 (en) * 2016-03-23 2017-09-28 Prothix Bv Monoclonal antibodies against the active site of factor xi and uses thereof
WO2018116267A2 (en) * 2016-12-23 2018-06-28 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
WO2018116255A1 (en) * 2016-12-23 2018-06-28 Novartis Ag Factor xi antibodies and methods of use
WO2018145533A1 (zh) * 2017-02-10 2018-08-16 上海仁会生物制药股份有限公司 抗凝血因子xi抗体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
TWI313299B (en) 2000-11-30 2009-08-11 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
PL2373691T3 (pl) 2008-12-18 2019-07-31 Oregon Health & Science University PRZECIWCIAŁA ANTY-fXI I SPOSOBY ZASTOSOWANIA
MX362454B (es) 2012-05-10 2019-01-18 Bayer Pharma AG Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos.
KR102236367B1 (ko) 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
AU2015232352B2 (en) 2014-03-17 2021-02-18 Mitsubishi Tanabe Pharma Corporation Antibody-fynomer conjugates
JP7252760B2 (ja) * 2016-01-22 2023-04-05 メルク・シャープ・アンド・ドーム・エルエルシー 抗凝固因子ｘｉ抗体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016207858A1 (en) * 2015-06-26 2016-12-29 Novartis Ag Factor xi antibodies and methods of use
CN107922505A (zh) * 2015-06-26 2018-04-17 诺华股份有限公司 凝血因子xi抗体及使用方法
WO2017162791A1 (en) * 2016-03-23 2017-09-28 Prothix Bv Monoclonal antibodies against the active site of factor xi and uses thereof
WO2018116267A2 (en) * 2016-12-23 2018-06-28 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
WO2018116255A1 (en) * 2016-12-23 2018-06-28 Novartis Ag Factor xi antibodies and methods of use
WO2018145533A1 (zh) * 2017-02-10 2018-08-16 上海仁会生物制药股份有限公司 抗凝血因子xi抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STUART RUDIKOFF等: "Single amino acid substitution altering antigen-binding specificity", PROC. NAT. ACAD. SCI., vol. 79, 31 March 1982 (1982-03-31), pages 1979 - 1983 *

Also Published As

Publication number Publication date
EP3957652A1 (en) 2022-02-23
WO2020211674A1 (zh) 2020-10-22
EP3957652A4 (en) 2023-06-21
JP2022528595A (ja) 2022-06-15
CN117186232A (zh) 2023-12-08
KR20210151774A (ko) 2021-12-14
US20220162338A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
TWI754157B (zh) 抗ｔｉｇｉｔ抗體及其用途
CN110662770A (zh) 结合凝血因子ix和凝血因子x的双特异性抗体
JP7028471B2 (ja) 第ｘｉ因子の活性部位に対するモノクローナル抗体及びその使用
TW201728602A (zh) 抗凝固因子ｘｉ抗體
BR112014001104B1 (pt) Anticorpo monoclonal antifator xii/xiia-beta ou fragmento de ligação ao antígeno do mesmo, seu método de produção, ácido nucleico, vetor, dispositivo médico e composição farmacêutica
CA2787566A1 (en) Anticoagulant antidotes
BR112012028306A2 (pt) anticorpos para proteína 6 relacionada com lipoproteína de baixa densidade (lrp6) e seus fragmentos, seu uso, ácidos nucléicos, vetores, bem como composições farmacêuticas e combinações
CN112955473B (zh) 特异性结合vegf和ang2的双特异性抗体
CN107531797B (zh) 凝血酶抗体、其抗原结合片段及医药用途
JPWO2015125904A1 (ja) 新規抗ヒトｐａｉ−１抗体
CN113474374A (zh) 抗FXI/FXIa抗体及其用途
WO2022002249A1 (zh) 抗FXI/FXIa抗体、其抗原结合片段及医药用途
CN112442127A (zh) 针对tfpi的单克隆抗体
JP7454106B2 (ja) 新規な抗ａ２ａｐ抗体およびその使用
WO2019096294A1 (zh) 凝血酶抗体、其抗原结合片段及医药用途
WO2023285525A1 (en) Novel fab dimers
TW202241964A (zh) 因子xia抑制劑之抗體及抗原結合肽及其用途
NZ619385B2 (en) Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40052551

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination